These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21211899)

  • 1. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
    Finelli A; Trottier G; Lawrentschuk N; Sowerby R; Zlotta AR; Radomski L; Timilshina N; Evans A; van der Kwast TH; Toi A; Jewett MA; Trachtenberg J; Fleshner NE
    Eur Urol; 2011 Apr; 59(4):509-14. PubMed ID: 21211899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
    Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
    BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-alpha reductase inhibitors in men undergoing active surveillance for prostate cancer: impact on treatment and reclassification after 6 years follow-up.
    Ashrafi AN; Shin T; Marien A; Clifford T; Shoji S; Iwata T; Iwata A; Oishi M; Chopra S; Cai J; Ukimura O; Bahn D; Gill IS; Abreu AL
    World J Urol; 2021 Sep; 39(9):3295-3307. PubMed ID: 33683411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.
    Hong SK; Oh JJ; Lee S; Lee HM; Byun SS; Choe G; Lee SE
    Prostate; 2012 Aug; 72(11):1187-92. PubMed ID: 22161951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
    Bul M; Zhu X; Valdagni R; Pickles T; Kakehi Y; Rannikko A; Bjartell A; van der Schoot DK; Cornel EB; Conti GN; Boevé ER; Staerman F; Vis-Maters JJ; Vergunst H; Jaspars JJ; Strölin P; van Muilekom E; Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2013 Apr; 63(4):597-603. PubMed ID: 23159452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
    Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin use and time to progression in men on active surveillance for prostate cancer.
    Jayalath VH; Nayan M; Finelli A; Komisarenki M; Timilshina N; Kulkarni GS; Fleshner NE; Bhindi B; Evans A; Zlotta AR; Hamilton RJ
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):509-515. PubMed ID: 29875433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
    Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
    Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
    Azoulay L; Eberg M; Benayoun S; Pollak M
    JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
    Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
    Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.